


## Plenary Speech 1P.3

# Why Nano technology ? Why now? And what might its impact on Electronics

Tuesday, March 23

9:45am-10:15am



**Larry Bock**  
CEO, Nanosys Inc.

Nanotechnology is dramatically changing electronics, through the development of nano-enabled systems. These systems incorporate novel nanostructures that integrate functional complexity directly into each individual nanoparticle, enabling the low-cost fabrication of revolutionary high-value, high-performance applications in a broad range of industries from life and physical sciences to information technology and communications to renewable energy to defense. These nanostructures include nanowires, nanorods, nanotetrapods and nanodots formed from all of the industrially important semiconductor materials (Group II-VI, III-V and IV) as their principal active elements. These systems exploit the fundamentally new and unique electronic, optical, magnetic, interface and integration properties associated with materials on the nanometer-scale. The initial applications include exquisitely sensitive chemical and biological sensors, high performance large area macroelectronics and lightweight high efficiency conformal photovoltaics. This talk will describe why now is the right time to focus on nanotechnology and how one company is using these ideas to revolutionize electronics.

### About Larry Bock

Mr. Bock is the Founder and Executive Chairman of Nanosys, Inc. He is also General Partner of CW Group, where he focuses on seed stage *de novo* start-ups in the life and physical sciences. Mr. Bock was the Founder and Initial CEO of ARIAD Pharmaceuticals (NASDAQ: ARIA – *intra cellular signal transduction*), Neurocrine Biosciences (NASDAQ: NBIX – *neuroimmunology*), Pharmacopeia (NASDAQ: PCOP – *combinatorial chemistry*), GenPharm International (acquired by MedaRx – *transgenic animals*), Argonaut Technologies (NASDAQ: AGNT – *combinatorial chemistry*), Caliper Technologies (NASDAQ: CALP – *lab-on-a-chip*), Illumina Technologies (NASDAQ: ILMN – *array based optical sensors*), IDUN Pharmaceuticals (Private – *apoptosis*) and FASTTRACK Systems (Private – *accelerated clinical development*). Mr. Bock was a co-founder of Athena Neurosciences (NASDAQ: ATHN, acquired by Elan Pharmaceuticals for \$700M – *molecular neurobiology*), Vertex Pharmaceuticals (NASDAQ: VRTX – *rational drug design*), and Onyx Pharmaceuticals (NASDAQ: ONXX – *molecular oncology*). Mr. Bock started his career as a Researcher at Genentech, Inc. in the field of infectious diseases. He was selected by Venture Capital Journal as one of the Ten Most Influential Venture Capitalists, by Red Herring as one of the Top Ten Innovators and by Small Times as Innovator of the Year and Top 3 Business Leaders of the Year. He is a Member of the Advisory Board and the Technology Advisory Board of the NanoBusiness Alliance and the Advisory Board of the Faculty of Chemistry at the University of California, Berkeley. He received his B.A. in Biochemistry from Bowdoin College and his M.B.A. from the Anderson School at UCLA.